HRTX
Heron Therapeutics Inc
$
1.970
- Overview
- Forecast
- Valuation
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.980
Open
1.870
VWAP
1.92
Vol
1.26M
Mkt Cap
300.55M
Low
1.8506
Amount
2.42M
EV/EBITDA(TTM)
--
Total Shares
150.65M
EV
384.37M
EV/OCF(TTM)
--
P/S(TTM)
2.06
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF, HTX-019, and HTX-034. HTX- ZYNRELEF is a dual-acting local anaesthetic that delivers a fixed-dose combination of the local anaesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-019 is an investigational agent for the prevention of postoperative nausea and vomiting in adults. HTX-034 is a product candidate for postoperative pain management.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
42.83M
+5.03%
0.000
-100%
39.62M
+20.75%
-0.005
-83.33%
37.93M
+5.3%
-0.015
-75%
Estimates Revision
The market is revising Downward the revenue expectations for Heron Therapeutics, Inc. (HRTX) for FY2025, with the revenue forecasts being adjusted by -0.78% over the past three months. During the same period, the stock price has changed by 14.53%.
Revenue Estimates for FY2025
Revise Downward
-0.78%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+14.53%
In Past 3 Month
3 Analyst Rating
221.32% Upside
Wall Street analysts forecast HRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HRTX is 6.33 USD with a low forecast of 4.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
221.32% Upside
Current: 1.970
Low
4.00
Averages
6.33
High
9.00
221.32% Upside
Current: 1.970
Low
4.00
Averages
6.33
High
9.00
Needham
Serge Belanger
Strong Buy
Reiterates
$4
2025-04-11
Reason
Needham
Serge Belanger
Price Target
$4
2025-04-11
Reiterates
Strong Buy
Reason
Needham
Serge Belanger
Strong Buy
Reiterates
$4
2025-02-28
Reason
Needham
Serge Belanger
Price Target
$4
2025-02-28
Reiterates
Strong Buy
Reason
Needham
Serge Belanger
Strong Buy
Reiterates
$4
2024-12-04
Reason
Needham
Serge Belanger
Price Target
$4
2024-12-04
Reiterates
Strong Buy
Reason
Needham
Serge Belanger
Strong Buy
Maintains
$5 → $4
2024-11-13
Reason
Needham
Serge Belanger
Price Target
$5 → $4
2024-11-13
Maintains
Strong Buy
Reason
Needham
Serge Belanger
Strong Buy
Reiterates
$5
2024-09-25
Reason
Needham
Serge Belanger
Price Target
$5
2024-09-25
Reiterates
Strong Buy
Reason
Needham
Serge Belanger
Strong Buy
Reiterates
$5
2024-08-07
Reason
Needham
Serge Belanger
Price Target
$5
2024-08-07
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Heron Therapeutics Inc (HRTX.O) is 93.50, compared to its 5-year average forward P/E of -11.54. For a more detailed relative valuation and DCF analysis to assess Heron Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-11.54
Current PE
93.50
Overvalued PE
8.65
Undervalued PE
-31.73
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.38
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
4.10
Undervalued EV/EBITDA
-10.86
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
5.75
Current PS
1.59
Overvalued PS
10.89
Undervalued PS
0.62
Financials
Annual
Quarterly
FY2025Q1
YoY :
+12.21%
38.90M
Total Revenue
FY2025Q1
YoY :
-165.74%
3.15M
Operating Profit
FY2025Q1
YoY :
-183.39%
2.64M
Net Income after Tax
FY2025Q1
YoY :
-150.00%
0.01
EPS - Diluted
FY2025Q1
YoY :
-5.64%
-8.98M
Free Cash Flow
FY2025Q1
YoY :
+3.46%
78.26
Gross Profit Margin - %
FY2025Q1
YoY :
-174.31%
6.77
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
191.5K
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
HRTX News & Events
Events Timeline
2025-05-06 (ET)
2025-05-06
07:48:28
Heron Therapeutics raises FY25 adjusted EBITDA view to $4M-$12M from $0-$8M
2025-05-06
07:46:38
Heron Therapeutics reports Q1 EPS 1c, consensus (1c)
2025-05-06
07:40:14
Heron Therapeutics announces settlement agreement with Mylan
Sign Up For More Events
Sign Up For More Events
News
9.5
05-06NewsfilterHeron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates
7.0
05-06NewsfilterHeron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent Litigations
7.0
05-06SeekingAlphaHeron settles patent dispute with Viatris over antiemetic agents
Sign Up For More News
People Also Watch
CPSS
Consumer Portfolio Services Inc
8.850
USD
-2.64%
ATAI
ATAI Life Sciences NV
1.650
USD
+1.23%
NGNE
Neurogene Inc
17.990
USD
-7.12%
DMAC
DiaMedica Therapeutics Inc
4.200
USD
+3.19%
ZYXI
Zynex Inc
2.480
USD
+13.24%
EIC
Eagle Point Income Company Inc
14.170
USD
+0.43%
AENT
Alliance Entertainment Holding Corp
2.920
USD
+13.18%
TZOO
Travelzoo
13.700
USD
-0.15%
LUNG
Pulmonx Corp
3.430
USD
+0.29%
HLXB
Helix Acquisition Corp II
10.850
USD
-0.55%
FAQ
What is Heron Therapeutics Inc (HRTX) stock price today?
The current price of HRTX is 1.97 USD — it has increased 5.35 % in the last trading day.
What is Heron Therapeutics Inc (HRTX)'s business?
What is the price predicton of HRTX Stock?
What is Heron Therapeutics Inc (HRTX)'s revenue for the last quarter?
What is Heron Therapeutics Inc (HRTX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Heron Therapeutics Inc (HRTX)'s fundamentals?
How many employees does Heron Therapeutics Inc (HRTX). have?